Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01053312 · ClinicalTrials.gov registry record · Phase 3
PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT01053312 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 7 participants.
The verdict
NCT01053312, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocephalus (NPH).
Interventions
- DRUG [18F] Flutemetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01053312
The ClinicalTrials.gov registry entry for NCT01053312 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] Flutemetamol is the first listed.
NCT01053312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01053312 about?
NCT01053312 is a clinical study titled "PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus". This study will determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocep...
What is the current status of trial NCT01053312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2009-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01053312?
The interventions under investigation include: [18F] Flutemetamol (DRUG).
Who is sponsoring clinical trial NCT01053312?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.